On March 27, 2025 NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering disruptive, nanotherapeutic approaches to revolutionize treatment outcomes for millions of patients, reported the first data from the completed dose escalation part of a Phase 1 study sponsored by The University of Texas MD Anderson Cancer Center ("MD Anderson") evaluating radiotherapy-activated NBTXR3 (JNJ-1900)1 as a second or later line (2L+) therapy for patients with locally advanced non-small cell lung cancer ("NSCLC") amenable to re-irradiation (Press release, Nanobiotix, MAR 27, 2025, View Source [SID1234651532]). These data will be presented at the 2025 European Lung Cancer Conference by study principal investigator Dr. Saumil Gandhi.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ABSTRACT #207P: Phase 1 Study of Reirradiation ("ReRT") with NBTXR3 (JNJ-1900) for Inoperable Locoregional Recurrent Non-Small Cell Lung Cancer ("NSCLC")
Saumil J. Gandhi, MD, PhD, Enoch Chang, MD, Aileen Chen, MD, Stephen G. Chun, MD, Steven H. Lin, MD, PhD, Rachel C. Maguire, BS, Matthew S. Ning, MD, MPH, Julianna K. Bronk, MD, PhD, David Qian, MD, Joe Y. Chang, MD, PhD, James W. Welsh, MD, Zhongxing Liao, MD, Rahul A. Sheth, MD, Roberto F. Casal, MD

Locoregional recurrence occurs in 30-40% of patients with locally advanced NSCLC after treatment with definitive chemoradiation. Historically, patients who are amenable to re-irradiation are often limited to palliative doses due to associated toxicities. As such, strategies to enhance the therapeutic ratio of radiotherapy are needed to improve treatment outcomes.

"Patients with recurrence after prior radiation therapy for locally advanced lung cancer face limited therapeutic options and significant challenges in achieving durable disease control," said Saumil Gandhi, MD, PhD, Department of Thoracic Radiation Oncology, Division of Radiation Oncology at MD Anderson. "These data underscore the need for continued therapeutic innovation for these patients and highlight the potential of NBTXR3 (JNJ-1900) as a novel approach to improving patient outcomes."

Results from the completed dose escalation part of the study demonstrated a favorable safety profile with no dose-limiting toxicities (DLTs), and no Grade 3 or higher SAEs related to NBTXR3. Injection feasibility was confirmed, and the recommended phase 2 dose (RP2D) was established at 33% of gross tumor volume.

Promising early efficacy signals were observed. Preliminary review of survival data from 12 patients showed 12-month LPFS of 64% (median 18.6 months) and 12-month OS of 83% (median 30.2 months), further supporting the potential clinical benefit of NBTXR3 (JNJ-1900) in this patient population.

"The Nanobiotix team is encouraged by these early findings, which suggest NBTXR3 (JNJ-1900) could offer a new therapeutic option for patients with no alternatives after prior treatments have failed," said Louis Kayitalire, MD, Nanobiotix Chief Medical Officer. "Notably, these results were observed in patients who resisted prior curative radiation doses and that were treated with JNJ-1900 (NBTXR3) activated by a lower radiation dose. As we advance the study’s expansion phase, we look forward to further evaluating NBTXR3 (JNJ-1900)’s potential to improve patient outcomes."

The expansion phase of the study is ongoing, with 5/12 patients injected to date.

About JNJ-1900 (NBTXR3)

NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. Its proof-of-concept was achieved in soft tissue sarcomas for which the product received a European CE mark in 2019. The product candidate’s physical mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Given the physical MoA, Nanobiotix believes that NBTXR3 could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly immune checkpoint inhibitors.

Radiotherapy-activated NBTXR3 is being evaluated across multiple solid tumor indications as a single agent or in combination with anti-PD-1 immune checkpoint inhibitors, including in NANORAY-312—a global, randomized Phase 3 study in locally advanced head and neck squamous cell cancers. In February 2020, the United States Food and Drug Administration granted regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy—the same population being evaluated in the Phase 3 study.

Given the Company’s focus areas, and balanced against the scalable potential of NBTXR3, Nanobiotix has engaged in a collaboration strategy to expand development of the product candidate in parallel with its priority development pathways. Pursuant to this strategy, in 2019 Nanobiotix entered into a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to sponsor several Phase 1 and Phase 2 studies evaluating NBTXR3 across tumor types and therapeutic combinations. In 2023, Nanobiotix announced a license agreement for the global co-development and commercialization of NBTXR3 with Janssen Pharmaceutica NV, a Johnson & Johnson company.

On March 27, 2025 Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, reported the analytical validation of NavDx+Gyn, an important extension of the NavDx blood test. NavDx+Gyn is a cell-free DNA-based fragmentomic profiling assay that enhances the detection and monitoring of human papillomavirus (HPV)-driven gynecologic cancers (Press release, Naveris, MAR 27, 2025, View Source [SID1234651549]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Leveraging the robust foundation of the NavDx test, which has been validated in over 35 peer-reviewed publications and utilized in nearly 100,000 patient-physician encounters, NavDx+Gyn expands detection capabilities to include fourteen high-risk HPV types associated with cervical, vaginal, and vulvar cancers. This new blood test has been rigorously validated to provide exceptional analytical specificity and sensitivity, setting a new standard for early detection and monitoring of these cancers.

The analytical validation, published in the Journal Diagnostics, confirms that NavDx+Gyn achieves outstanding limits of detection and quantitation, ensuring dependable detection of HPV types at very low concentrations. The assay’s performance was extensively tested across multiple analytical metrics including accuracy, precision, and linearity, with results underscoring its high-quality standards.

"NavDx+Gyn is a significant enhancement in the non-invasive surveillance of HPV-associated gynecologic cancers," said Dr. Piyush B. Gupta, PhD, Executive Chairman, Chief Science & Technology Officer, and Founder of Naveris. "Early detection is vital for effective management and treatment of these cancers."

The development of NavDx+Gyn comes at a critical time, addressing the pressing need for advanced diagnostic tools in the face of the global burden of HPV-related cancers and the limitations of current diagnostic methods. By offering a reliable, non-invasive testing option, NavDx+Gyn aims to change the landscape of cancer surveillance and offer new hope to thousands of women worldwide.

"Naveris is committed to advancing healthcare equity and improving outcomes for cancer patients through state-of-the-art diagnostics," added Dr. Barry M. Berger, MD, Chief Medical Officer of Naveris. "NavDx+Gyn embodies our dedication to harnessing innovation to improve patient care through early detection."

Hutcheson J., Conway D., Kumar S., Wiseman C., Chakraborty S., Skrypkin E., Horan M., Gunning A., Williams C.K., Kuperwasser C., Naber S.P., and Gupta P.B. Analytical Validation of NavDx+Gyn, a cfDNA-Based Fragmentomic Profiling Assay for HPV-Driven Gynecologic Cancers. Diagnostics 2025, 15(7), 825. View Source

On March 27, 2025 PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, reported a clinical programs update and announced financial results for the full year ended December 31, 2024 (Press release, PDS Biotechnology, MAR 27, 2025, View Source [SID1234651534]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased with the progress made over the past year and in recent weeks, culminating with the initiation of our VERSATILE-003 Phase 3 clinical trial evaluating Versamune HPV in recurrent/metastatic ("R/M") HPV16-positive head and neck squamous carcinoma ("HNSCC")," said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech. "Patients with HPV16-positive HNSCC represent a large and rapidly growing subgroup in need of targeted therapies to treat the underlying cause of the cancer. Considering the strength and durability of the clinical responses observed in our VERSATILE-002 study, we are excited that this registrational trial is underway and are confident in the potential of our innovative combination therapy to improve patient outcomes and enhance the standard of care. In the coming weeks, we expect to continue activating additional clinical sites, and look forward to the progression of this registrational trial."

Clinical Strategy Summary

•
Phase 3 VERSATILE-003 Trial in HPV16-positive first-line recurrent and/or metastatic HNSCC

•
Announced activation of the first site in March 2025

•
Trial designed to include approximately 350 patients

•
PDS Biotech is aligned with the U.S. Food and Drug Administration ("FDA") on the design of the registrational trial and clinical endpoints.

■
Two-arm controlled trial with 2:1 randomization

■
Median overall survival is primary endpoint

■
Design based on strong and durable responses seen in the VERSATILE-002 trial

■
Interim readouts included in study design

•
The Company received Fast Track designation from the FDA for the combination of Versamune HPV and pembrolizumab in R/M HNSCC.

•
For more information on VERSATILE-003, visit ClinicalTrials.gov (Identifier: NCT06790966)

•
In March 2025, announced FDA Clearance of Investigational New Drug ("IND") application for the combination of Versamune MUC1 and PDS01ADC to treat MUC1-positive unresectable, metastatic colorectal carcinoma.

•
Phase 1/2 clinical trial evaluating the proprietary combination to be run under PDS Biotech’s Cooperative Research and Development Agreement with the National Cancer Institute

•
Second Versamune platform candidate targets MUC1-positive solid tumors

•
In October 2024, updated results from the IMMUNOCERV Phase 2 clinical trial in locally advanced cervical cancer patients treated with Versamune HPV and chemoradiotherapy were presented at the 66th American Society for Radiation Oncology (ASTRO) Annual Meeting.

•
In October 2024, the rationale and design of a recurrent prostate cancer trial combining Xtandi + PDS01ADC vs. Xtandi were presented at the 12th Annual Meeting of the International Cytokine and Interferon Society (Cytokines 2024).

Full Year 2024 Financial Results

Net loss for the year ended December 31, 2024, was approximately $37.6 million, or $1.03 per basic and diluted share, compared to a net loss of $42.9 million, or $1.39 per basic and diluted share, for the year ended December 31, 2023. The reduced net loss was primarily the result of decreased operating expenses, partially offset by increased net interest expense.

Research and development expenses for the year ended December 31, 2024, were $22.6 million, compared to $27.8 million for the year ended December 31, 2023. The decrease of $5.2 million was primarily attributable to decreases in clinical costs of $4.1 million, personnel costs of $1.0 million and professional fees of $0.1 million.

General and administrative expenses for the year ended December 31, 2024, were $13.8 million, compared to $15.3 million for the year ended December 31, 2023. The $1.5 million decrease was primarily attributable to decreases in professional fees of $1.3 million and facilities costs of $0.2 million.

Total operating expenses for the year ended December 31, 2024, were $36.3 million, compared to $43.0 million for the year ended December 31, 2023.

Net interest expense was $2.2 million for the year ended December 31, 2024, compared to $1.3 million for the year ended December 31, 2023. The change was due to increased debt interest and lower interest income on the Company’s cash balances.

On February 27, 2025, the Company announced an up to $22 million registered direct offering. The securities purchase agreements with new and existing healthcare focused institutional investors included $11 million of upfront gross proceeds, with up to an additional $11 million of aggregate gross proceeds upon cash exercise in full of warrants issued to the investors.

The Company’s cash balance as of December 31, 2024, was $41.7 million.

Conference Details

Date: March 27, 2025
Time: 8:00 a.m. Eastern Time
Dial-in: 1-877-704-4453 (Domestic) or 1-201-389-0920 (International)
Webcast Registration: Click Here
Call MeTM Registration: Click Here (Available 15 minutes prior to call)

On March 27, 2025 InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, reported the 2024 annual results as of 31 December 2024 (Press release, InnoCare Pharma, MAR 27, 2025, View Source [SID1234651550]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Financial Highlights

Revenue of Orelabrutinib increased by 49.1% to RMB 1,000.4 million1 in 2024, mainly driven by rapid growth of marginal zone lymphoma (MZL) indication and strong commercial execution. Total revenue increased by 36.7% to RMB 1,009.4 million in 2024.
Gross Profit increased by 42.8% to RMB 871.0 million in 2024, with a gross profit margin of 86.3%, representing an increase of 3.7 percentage points, mainly due to the reduction in the unit cost of sales.
Research and Development Expenses increased by 8.4% to RMB 814.0 million in 2024, primarily due to increased investment in advanced technology platforms and heightened spending on global clinical trials.
The Loss decreased by 29.9% to RMB 452.9 million in 2024.
Cash and Related Accounts Balance2 stood at approximately RMB 7.8 billion as of 31 December 2024. This robust cash position provides InnoCare with flexibility to expedite clinical development and invest in a competitive pipeline.
Accelerating Globalization

China’s innovative drugs have become a new focus of the global pharmaceutical industry, and its innovation capabilities are increasingly recognized worldwide. In January 2025, InnoCare Pharma and KeyMed Biosciences entered into an exclusive license agreement with Prolium Bioscience (Prolium) for the development and commercialization of ICP-B02 (CM355), a CD20xCD3 bispecific antibody. Under the terms of the agreement, Prolium will have the exclusive right to develop, register, manufacture and commercialize ICP-B02 in the non-oncology field globally and in the oncology field in ex-Asia regions. InnoCare and KeyMed will receive aggregate payments of up to US$ 520 million, including upfront and near-term payments and other payments subject to the achievement of certain clinical, regulatory and commercial milestones, as well as a minority equity stake in Prolium. InnoCare and KeyMed are also eligible to receive tiered royalties on future net sales of any product resulting from the collaboration.

InnoCare will continue to strengthen the globalization of its other promising pipeline assets. As part of its BD strategy, the Company has been actively exploring collaboration and licensing opportunities for key assets, with a focus on expanding its presence outside of China. The Company remains committed to accelerating the global reach of its products through strategic partnerships, as well as strengthening regulatory and clinical capabilities in key markets.

Dr. Jasmine Cui, the Co-founder, Chairwoman and CEO of InnoCare, said, "2024 marks the first year of the rapidly evolving InnoCare 2.0. Our commercial growth continued to accelerate, our R&D pipelines achieved key milestones, and our internationalization efforts gained momentum. 2025 marks our 10th anniversary. We will continue to pursue original innovation, advance multiple new molecules into clinical development, and accelerate multiple Phase III registration clinical studies in China and around the world. We will further strengthen our market expansion and establish a long-term successful commercial strategy, and further advance our globalization to bring more innovative projects to the global stage."

Building A Leading Franchise in Hemato-Oncology

With orelabrutinib as the backbone therapy, it plays a central role in InnoCare’s extensive pipeline in hemato-oncology. Alongside orelabrutinib, tafasitamab’s BLA was accepted, and ICP-248 (mesutoclax) entered into a Phase III clinical trial in combination with orelabrutinib for the fixed-duration treatment of 1L CLL/SLL in the first quarter of 2025. Together, orelabrutinib, tafasitamab and ICP-248 form a robust product combination that will establish a solid foundation in hematology-oncology. With this powerful combination and ongoing developments from both internal and external sources, InnoCare is dedicated to becoming a leading player in hemato-oncology both in China and worldwide. The Company remains committed to addressing major diseases, such as NHL, leukemia and multiple myeloma, through both monotherapies and combination therapies to provide effective solutions for patients globally.

Orelabrutinib

All three approved indications, including relapsed and refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (r/r CLL/SLL), r/r mantle cell lymphoma (r/r MCL) and r/r marginal zone lymphoma (r/r MZL), have been covered in the National Reimbursement Drug List while maintaining stable pricing. Orelabrutinib has been approved as the first and only BTK inhibitor for r/r MZL in China. Meanwhile, commercial capabilities have undergone significant enhancement. The dedicated commercial team has been optimized to operate with heightened efficiency and strategic focus, ensuring effective execution of the market initiatives. All of the above factors resulted in an 49.1% increase in orelabrutinib’s revenue in 2024.

The new drug application (NDA) of orelabrutinib for the first-line treatment of CLL/SLL was accepted in China.
In Australia, the NDA of orelabrutinib for r/r MCL was submitted.
In Singapore, the NDA of orelabrutinib for r/r MZL was submitted.
The Company is accelerating a global Phase III study of orelabrutinib for the first-line treatment of MCL, and a Phase III confirmatory study of orelabrutinib for MZL.
Tafasitamab

The NMPA accepted and granted priority review to the Biologics License Application (BLA) for tafasitamab in combination with lenalidomide for adult patients with r/r diffuse large B-cell lymphoma (DLBCL) who are not eligible for Autologous Stem Cell Transplant.
Based on a single arm, open label Phase II registrational trial of tafasitamab in combination with lenalidomide in patients with r/r DLBCL, the overall response rate (ORR) was 73.1%, with 34.6% of patients achieving complete response.
The result of a five-year study from L-MIND shows that tafasitamab provided prolonged, durable responses in patients with r/r DLBCL.
Tafasitamab in combination with lenalidomide was approved in the region of Hong Kong, Macau and Taiwan, and approved for use in Bo’ao and Greater Bay Area with first prescription issued respectively.
Mesutoclax (ICP-248)

The first patient has been dosed in the Phase III clinical trial of ICP-248 in combination with orelabrutinib as a first line therapy for the treatment of CLL/SLL patients in China.
As of the latest update, 42 patients with treatment-naïve (TN) CLL/SLL were enrolled and treated with ICP-248 in combination with orelabrutinib, with no clinical or laboratory evidence of tumor lysis syndrome (TLS) observed. At a median combination therapy duration of 5.5 months, the ORR and uMRD (undetectable minimal residual disease) rate were 100% and 46.2% respectively (MRD check point: 12 weeks after initiation of combo treatment).
The Company is applying for registrational trial of BTKi-treated r/r MCL in China.
The clinical trials of ICP-248 for the first line treatment of acute myeloid leukemia (AML) are ongoing in both China and globally.
ICP-248 is a novel, orally bioavailable BCL2 selective inhibitor, developed as monotherapy or in combination with orelabrutinib for the treatment of CLL/SLL, MCL, AML and other NHLs.
ICP-490

ICP-490 is a proprietary, orally available small molecule that modulates the immune system and other biological targets through multiple mechanisms of action. Phase I/II dose escalation and expansion studies with MM and NHL patients are underway in China.
ICP-490 in combination with dexamethasone was well tolerated and the preliminary efficacy has been confirmed at the dose levels of 1.0mg + of ICP-490 in combination with dexamethasone in MM patients
Developing B-cell and T-cell Pathways in Autoimmune Diseases

Autoimmune diseases can affect almost every organ in the body and may arise at any stage of life. The global market for autoimmune disease therapeutics anticipated to reach $185 billion by 20293. The Company has fortified its powerful discovery engine on cutting-edge global targets for the development of autoimmune therapeutics through B-cell and T-cell pathways, with the aim of delivering first-in-class and/or best-in-class treatments to address the massive unmet clinical needs and strong market potential in China and globally.

Orelabrutinib

MS: In September 2024, the Company and the FDA reached an agreement to initiate a Phase III study of orelabrutinib in patients with Primary Progressive Multiple Sclerosis (PPMS). In February 2025, the FDA also approved the Phase III trial protocol of orelabrutinib in the Secondary Progressive Multiple Sclerosis (SPMS). The Company is accelerating the initiation of the Phase III studies for PPMS and SPMS, demonstrating its ongoing commitment to developing innovative and effective treatments to address unmet medical needs in patients with progressive multiple sclerosis (PMS).
The Phase II results of orelabrutinib for the treatment of MS were presented at the 10th annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS). The study showed that orelabrutinib was highly effective in treating patients with relapsing-remitting multiple sclerosis (RRMS). The 80 mg once daily (QD) dose showed the best efficacy and safety profile, thus was selected for Phase III studies in progressive MS.
ITP: The Company is accelerating patient enrolment in the Phase III registrational trial of orelabrutinib for the treatment of Immune Thrombocytopenia (ITP) and expects to submit the NDA application in the first half of 2026. By leveraging the BTK inhibitor’s advantage in ITP, such as decreased macrophage-mediate platelet destruction and reduced production of pathogenic autoantibodies, orelabrutinib is well positioned to become a preferred BTK inhibitor in the field of ITP.
SLE: The Phase IIa trial for systemic lupus erythematosus (SLE) demonstrated positive results, with remarkable SLE Responder Index (SRI)-4 response rates observed in a dose dependent manner, along with trends indicating a reduction in proteinuria levels. The Phase IIb clinical trial for orelabrutinib in SLE has completed patient enrollment in 2024, with data readout expected in the fourth quarter of 2025. Orelabrutinib is the first and only BTK inhibitor globally, to have ever demonstrated efficacy in Phase II SLE trials.
Soficitinib (ICP-332)

The company is accelerating patient enrollment in the Phase III trial of ICP-332 for atopic dermatitis (AD), with over 110 patients enrolled to date.
The Phase II/III trial for vitiligo was initiated in China, and the Company is planning the Phase II global trial for prurigo nodularis.
In the U.S., the Phase I trial of ICP-332 was completed, and the Company will engage with the FDA regarding the subsequent clinical development plan.
Data on ICP-332 for the treatment of patients with moderate-to-severe AD has been released at the 2024 American Academy of Dermatology (AAD) Annual Meeting as a late-breaking oral presentation.
ICP-332 demonstrated an outstanding efficacy and safety profile. ICP-332 achieved multiple efficacy endpoints in the 80 mg QD and 120 mg QD dosing groups respectively, including the percentage change in Eczema Area and Severity Index (EASI) score from baseline, EASI 50, EASI 75, EASI 90 (improvement of at least 50%, 75% and 90% in EASI score from baseline), Investigator’s Global Assessment (IGA) 0/1 (score of 0 ‘clear’ or 1 ‘almost clear’) with >= 2 points improvement, and Pruritus Numerical Rating Scale (NRS) score from baseline, etc.
The mean percentage change from baseline of the EASI 50 score reached 78.2% and 72.5% at the 80 mg QD and 120 mg QD groups respectively, both with a highly significant P value, compared to 16.7% for the patients receiving placebo. The percentages of patients achieving at least 75% improvement in EASI 75 were significantly higher in the ICP-332 80 mg QD (64.0%) and 120 mg QD (64.0%) groups than that of placebo (8.0%). These results exceed the reported efficacies of multiple approved innovative drugs after 12 or 16 weeks of treatment (not a head-to-head comparison).
ICP-332 was safe and well tolerated in AD patients. The overall incidence rates of adverse events (AEs) and AEs related to infections and infestations in the two treatment groups were comparable to that of the placebo group.
ICP-332 is a novel tyrosine kinase 2 (TYK2) inhibitor that is being developed for the treatment of various T-cell related autoimmune disorders.
ICP-488

The first patient has been dosed in the Phase III registrational trial of ICP-488 for the treatment of moderate-to-severe plaque psoriasis in China.
Data on ICP-488 for the treatment of patients with moderate-to-severe plaque psoriasis has been released at the 2025 AAD Annual Meeting as a late-breaking oral presentation. The study results demonstrated that ICP-488 is highly effective in treating psoriasis at both the 6 mg QD and 9 mg QD doses. Moreover, ICP-488 exhibited favorable safety and tolerability profiles, reinforcing its potential as a valuable treatment option for moderate-to-severe psoriasis patients.
At week 12, the percentage of patients achieving PASI 75 was significantly superior in the ICP-488 6 mg QD group (77.3%) and the 9 mg QD group (78.6%) than that of the placebo group (11.6%); the percentages of subjects achieving PASI 90 and sPGA of 0 (clear) or 1 (almost clear) were also significantly higher in the ICP-488 6 mg QD group (36.4%, 70.5%) and 9 mg QD group (50.0%, 71.4%) compared to the placebo group (0%, 9.3%).
All treatment emergent adverse events (TEAEs) and treatment-related adverse events (TRAEs) were mild or moderate.
ICP-488 is a potent and selective TYK2 allosteric inhibitor that binds to the pseudo kinase JH2 domain of TYK2 and blocks IL-23, IL12, type 1 IFN, and other cytokine receptors.
IL-17 Small Molecule

IL-17 (Interleukin-17) is a pro-inflammatory cytokine that plays a critical role in the pathogenesis of several autoimmune and inflammatory diseases, such as psoriasis, rheumatoid arthritis, and ankylosing spondylitis. Oral small molecules targeting IL-17 represent a new and promising class of therapeutics, offering the potential for easier administration, flexible dosing, and broader patient access. InnoCare identified a novel, orally available, small molecule that can potently block the binding of both IL-17AA and IL-17AF to IL-17R, thereby modulating immune responses and reducing inflammation.
Building Innovative Solid Tumor Assets

With ongoing efforts to address the growing needs in solid tumors, InnoCare is committed to building a competitive drug portfolio aimed at treating a broad range of solid tumor indications. The Company is expanding the scope of its pipeline through a combination of targeted therapies, immune-oncology approaches, and cutting-edge ADC technology. The R&D team is focused on discovering and developing novel platforms that target various solid tumors, utilizing innovative technologies to identify and advance potential drug candidates that offer significant clinical benefits. InnoCare’s proprietary ADC technology platform, alongside promising precision medicine candidates like ICP-723, positions the Company to establish a strong presence in the field of solid tumor treatment.

Zurletrectinib (ICP-723)

The Company has completed the Phase II registrational trial for ICP-723 in adult and adolescent patients (12+ years of age) with advanced solid tumors harboring NTRK gene fusions. The NDA is expected to be submitted at the end of March 2025.
Zurletrectinib was shown to overcome acquired resistance to the first generation TRK inhibitors, bringing hope for patients who failed prior TRKi therapy.
Zurletrectinib demonstrated outstanding efficacy with a good safety profile, achieving an ORR of 85.5%.
Registrational trial for pediatric patients (2 to 12) ongoing, targeting NDA submission in later 2025
ICP-189

The Company has completed the Phase 1b dose finding study of ICP189 combined with firmonertinib, with no DLTs observed. The dose expansion study is currently ongoing, and the Phase 1b data readout is expected in 2025.
InnoCare and ArriVent reached a clinical development collaboration to evaluate the anti-tumor activity and safety of the combination of InnoCare’s novel SHP2 allosteric inhibitor, ICP-189, with ArriVent’s third generation EGFR inhibitor firmonertinib in patients with advanced non-small cell lung cancer (NSCLC). Currently, the combination study is underway. NSCLC is the predominant subtype of lung cancer, accounting for approximately 85% of all cases4.
In-House Developed Antibody-Drug Conjugate (ADC) Platform

The Company has developed a cutting-edge ADC platform with proprietary linker-payload (LP) technologies, aimed at the delivery of potent and targeted therapies for cancer treatment. This platform allows for the creation of highly differentiated ADCs with improved efficacy and safety profiles. Key features of the platform include:
Novel connector: Irreversible connector to avoid linker detachment caused by instability.
Hydrophilic linker: enhancing ADC stability and achieving high drug-to-antibody ratio (DAR).
Novel payload: incorporating highly potent cytotoxic payloads with strong bystander killing effect.
The platform is expected to deliver ADCs with strong tumor-killing efficacy and an adequate therapeutic window, thereby broadening treatment options for cancer patients and improving their clinical outcomes. As the platform continues to evolve, the Company is poised to expand its portfolio with multiple differentiated ADC candidates, further advancing precision medicine in oncology.
ICP-B794: A Novel B7-H3 Targeted ADC for Solid Tumors

ICP-B794 is a novel ADC comprising a humanized anti-B7-H3 monoclonal antibody conjugated to in-house developed potent payload (a novel topoisomerase 1 inhibitor) via a protease-cleavable linker. This combination ensures precise targeting of tumor cells while minimizing off-target effects, offering a promising treatment for solid tumors such as lung cancer, esophageal cancer, nasopharyngeal cancer, head and neck squamous cell carcinomas, prostate cancer, etc. The company will submit an IND application for ICP-B794 in the first half of 2025.
ICP-B794 has demonstrated superior anti-tumor activity in animal model compared to other ADCs, and exhibited significant tumor-killing effect even in large tumors.
Leveraging AI to Drive Innovation and Enhance Efficiency

InnoCare is committed to harnessing the power of artificial intelligence (AI) to accelerate drug discovery, optimize research and development (R&D) processes, and improve operational efficiency. AI-driven technologies enable to analyze vast datasets, identify promising drug candidates with greater precision, and streamline clinical trial design. By integrating AI into various aspects of the operations, the Company will enhance decision-making, reduce development timelines, and increase the probability of success in bringing novel therapies to patients. Moving forward, InnoCare will continue to explore AI’s potential to drive innovation and create transformative treatment solutions.

To know more about the detailed financial data and business updates of InnoCare 2024 annual results, please log in to View Source

Conference Call Information

InnoCare will host a conference call at 8:30 p.m. Beijing time on March 27 in English and at 9:00 a.m. Beijing time in Chinese on March 28, 2024. Participants must register in advance of the conference call. Details are as follows:

For English conference call, please register through the below link:
View Source

For Chinese conference call, please register through the below link:
View Source

On March 27, 2025 Ascentage Pharma Group International (Ascentage Pharma) (NASDAQ: AAPG; HKEX: 6855) (referred hereinto as "Ascentage Pharma," the "Company," "we," "us" or "our"), a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in hematological malignancies, reported its unaudited financial results for the year ended December 31, 2024, and provided updates on key clinical and commercial developments (Press release, Ascentage Pharma, MAR 27, 2025, View Source [SID1234654252]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Dajun Yang, Chairman and Chief Executive Officer of Ascentage Pharma, said, "As we reflect on our achievements in 2024, I am delighted to report that Ascentage Pharma has made remarkable strides in advancing our mission to deliver innovative therapies to patients worldwide. The commercialization of olverembatinib in China has gained significant traction in 2024 and is poised for growth in 2025 as all approved indications of olverembatinib are now covered under China’s National Reimbursement Drug List (NRDL), markedly enhancing affordability and accessibility for patients across China."

He continued, "Our momentum continued with the advancement of lisaftoclax. In November 2024, the New Drug Application (NDA) for lisaftoclax for the treatment of relapsed and/or refractory chronic lymphocytic leukemia (R/R CLL) and small lymphocytic lymphoma (SLL) was accepted by the Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) with Priority Review designation. This acceptance marks a pivotal step toward bringing this novel therapy to patients in need."

"Our clinical development programs also achieved significant progress over the past year. In February 2024, olverembatinib received clearance by the U.S. Food and Drug Administration (FDA) to initiate a global registrational Phase III clinical trial (POLARIS-2), for patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with or without T315I mutation who have previously failed tyrosine kinase inhibitor (TKI) treatment. In 2024, we also received clearance to commence two registrational Phase III clinical trials for APG-2449, a focal adhesion kinase (FAK), third generation anaplastic lymphoma kinase (ALK) and receptor tyrosine kinase C-ros oncogene 1 (ROS1) inhibitor, for treatment of patients with non-small cell lung cancer (NSCLC). At the moment, we are conducting ten global registrational trials, including two that were cleared by the FDA, for our three late-stage products, olverembatinib, lisaftoclax and APG-2449. These milestones highlight our commitment to addressing unmet medical needs through rigorous clinical innovation."

"We believe Ascentage Pharma is on a transformative path to becoming a global leader in oncology innovation. The commercialization of olverembatinib in China, the progress of lisaftoclax, the continued development of our other clinical-stage small molecule drug assets, and our strategic agreement with Takeda Pharmaceuticals International AG (Takeda) reflect the strength of our pipeline and our ability to execute on our goals. In 2025, we remain focused on accelerating the development and delivery of life-changing therapies, expanding our global footprint, and creating sustainable value for all stakeholders."